The recent developments of the bio-tech giant
Intuitive Surgical (ISRG) paint a fairly positive picture when viewed in the context of their long-term outlook. Their latest
Q4 earnings not only beat Wall Street's expectations but also recorded
record revenues, alongside a surge in robotic surgeries. This growth comes despite the firm experiencing losses for seven straight sessions prior. There has been substantial buy/sell activity around the stock, with Baird reinstating a buy rating post FDA clearances. It's worth noting, however, that the company's valuation has faced scrutiny following the price decline. A number of significant players, including Y Intercept Hong Kong Ltd and Mn Services Vermogensbeheer B.V., have increased their stakes, while others, such as Jennison Associates LLC and Lockheed Martin Investment Management Co., have reduced theirs. The highlight is the company surpassing the milestone of
20 million global Da Vinci procedures. Despite some analysts voicing concerns about potential overvaluation, the consensus remains overwhelmingly positive on the stock, with targets being revised upwards.
Intuitive Surgical ISRG News Analytics from Wed, 17 Dec 2025 08:00:00 GMT to Sat, 24 Jan 2026 23:01:27 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -3
